'Mrd' presentation slideshows

CLEARANCE BLASTIQUE AU COURS DES LEUCEMIES AIGUES LYMPHOBLASTIQUE Gouider Emna

724 views • 43 slides

St James's Institute of Oncology

Flow- cytometric quantification of minimal residual disease (MRD) in myeloma: independent outcome prediction & sequential survival benefits per log tumour reduction. St James's Institute of Oncology. Andy C. Rawstron. MRD analysis for clinical trials in myeloma. Myeloma IX

496 views • 41 slides

Upfront Transplant Strategies in Aplastic Anemia

Upfront Transplant Strategies in Aplastic Anemia. Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood and Marrow Transplantation Group. #2. #1. Yes. No. Yes. #3. No.

505 views • 34 slides

?????????????

?????????????. Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood and Marrow Transplantation Group. #2. #1. Yes. No. Yes. #3. No. Yes. No.

497 views • 34 slides

?????????????

?????????????. Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood and Marrow Transplantation Group. #2. #1. Yes. No. Yes. #3. No. Yes. No.

453 views • 34 slides

Upfront Transplant Strategies in Aplastic Anemia

Upfront Transplant Strategies in Aplastic Anemia. Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood and Marrow Transplantation Group. #2. #1. Yes. No. Yes. #3. No.

435 views • 34 slides

Russische Aktien: Nachhaltiger Trend oder Zeit Gewinne mitzunehmen?

326 views • 25 slides

AML ??????? : ??????

AML ??????? : ??????. Hwei-Fang Tien, National Taiwan University Hospital. ??. ????????? ?????? ?????? ????????. ??. ????????? ?????? ?????? ????????. AML ???????. ???????? NPM1, IDH1/2, DNMT3A ,CEBPA, MLL-PTD ?????? : ? 30% t(8;21)/ RUNX1-RUNX1T1 inv(16)/ CBF ? -MYH11

397 views • 24 slides

Minimal Residual Disease analysis in childhood ALL

Minimal Residual Disease analysis in childhood ALL. Dr Jerry Hancock Scientific Co-ordinator of UKMRD Laboratory Network Bristol Genetics Lab. Survival in Childhood ALL. Survival. Prognostic factors used to direct therapy. Fixed factors

470 views • 20 slides

Using the MLL translocation as an MRD marker in infant ALL

Using the MLL translocation as an MRD marker in infant ALL. Rich Hathway Bristol Genetics Laboratories. Acute Lymphoblastic Leukaemia (ALL). ALL is a form of cancer that affects the lymphocyte producing cells in the bone marrow

457 views • 16 slides

CDGCHRONO

MRD- Implementation phasing. Phase 1. Phase 2. Phase 3. Phase 4. CDGCHRONO. Impl level 1. MAD. Impl level 2. AMS. Impl level 3. ATH. OSL. KEF. Impl level 4. CPH. HEL. LIS. LAX. BRU. SFO. ARN. BUD. CDG. VIE. Impl level 5. MXP. LIN. Other:. FRA.

251 views • 16 slides

Phase 1

MRD- Implementation phasing. Phase 1. Phase 2. Phase 3. Phase 4. Impl level 1. AMS. MAD. HEL. Impl level 2. ATH. Impl level 3. Impl level 4. ARN. BRU. CPH. LIN. LIS. MXP. BUD. OSL. VIE. Impl level 5. CDG. Other:. FRA.

234 views • 16 slides

AML2012 Overview

AML2012 Overview. Inv(16) and SR. HA 3 E. FLA. AD(x)E. CR. BM d22*. R. BM **. HAM. HA3E. FLA. MEC. FLAD(x). No CR. SCT for HR. Salvage therapy. MEC. MEC. Cytarabine 200 mg/m 2 12h ci iv. Day 6-12. Mitoxantrone 5 mg/m 2 iv. Day 6-10 Inf 1 hour. Etoposide 150 mg/m 2 iv.

125 views • 12 slides

MRD is a powerful prognostic factor in AML.

Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML). Although most pts with AML (> 80%) achieve CR following induction therapy, relapse is common and a major cause of treatment failure

109 views • 10 slides